Works Cited

1. Raintree. Tropical Plant Database: Curare. Available at http://www.rain-tree.com/curare.htm. Last accessed March 19, 2020.

2. Black J. Claude Bernard on the action of curare. BMJ. 1999;319(7210):622.

3. Carman JA. History of curare. Anaesthesia. 1968;23(4):706-707.

4. Griffith HR. Physiologic and clinical action of curare. Curr Res Anesth Analg. 1946;25:45-51.

5. Birmingham AT. Waterton and wouralia. Br J Pharmacol. 1999;126(8):1685-1689.

6. Bernard C. Morceaux Choisis et Préfacés par Jean Rostand. Paris: Gallimard; 1938.

7. West R. Curare in man. Proc R Soc Med. 1932;25(7):1107-1116.

8. Griffith H, Johnson GE. The use of curare in general anesthesia. Anesthesiology. 1942;3:418-420.

9. Beecher HK, Todd DP. A study of deaths associated with anesthesia and surgery. Ann Surg. 1954;140(1):2-34.

10. Hall JE. Excitation of skeletal muscle: neuromuscular transmission and excitation-contraction coupling. In: Hall JE, Guyton AC (eds). Guyton and Hall's Textbook of Medical Physiology. 13th ed. Philadelphia, PA: Elsevier, Inc.; 2016: 89-95.

11. Brull SJ. Physiology of neuromuscular transmission. In: Murray MJ, Rose SH, Wedel DJ, et al. (eds). Faust's Anesthesiology Review. 4th ed. Philadelphia, PA: Elsevier; 2015: 98-100.

12. Rossman AC. The physiology of the nicotinic acetylcholine receptor and its importance in the administration of anesthesia. AANA J. 2011;79(5):443-440.

13. Bowman WC. Neuromuscular block. Br J Pharmacol. 2006;147(Supple 1):S277-S286.

14. Martyn JA. Neuromuscular physiology and pharmacology. In: Miller RD (ed). Miller's Anesthesia. 8th ed. Philadelphia, PA: Elsevier; 2015: 423-443.

15. Calvey TN, Williams NE. Drugs that act on the neuromuscular junction. In: Calvey TN, Williams NE (eds). Principles and Practice of Pharmacology for Anesthetists. 5th ed. Malden, MA: Blackwell Publishing; 2008: 171-194.

16. Haas RE, Darsey DA, Powell D. Neuromuscular blocking agents, reversal agents, and their monitoring. In: Nurse Anesthesia. 6th ed. St. Louis, MO: Elsevier; 2018: 162-195.

17. Lien C, Eikermann M. Neuromuscular blockers and reversal drugs. In: Hemmings HC, Egan TD (eds.) Physiology and Pharmacology for Anesthesia: Foundations and Clinical Application. 2nd ed. Philadelphia, PA: Elsevier; 2019: 325-348.

18. Chambers SL, Ferry TG. Patients requiring mechanical ventilation. In: Hurd WW, Jernigan JG (eds). Aeromedical Evacuation: Management of Acute and Stabilized Patients. New York, NY: Springer-Verlag; 2003: 256-264.

19. Tobias JD, Lynch A, McDuffie A, Garrett JS. Pancuronium infusion for neuromuscular block in children in the pediatric intensive care unit. Anesth Analg. 1995;81(1):13-16.

20. Kobayashi O, Nagashima H, Duncalf D, et al. Direct evidence that pancuronium and gallamine enhance the release of norepinephrine from the atrial sympathetic nerve by inhibiting prejunctional muscarinic receptors. J Auton Nerv Syst. 1987;18(1):55-61.

21. Dalton DW, Tyers MB. A comparison of the muscarinic antagonist actions of pancuronium and alcuronium. J Auton Pharmacol. 1982;2(4):261-266.

22. Brinkmann M, Güenniker M, Freund U, Schieffer M, Peters J. Histamine plasma concentration and cardiovascular effects of non-depolarizing muscle relaxants: comparison of atracurium, vecuronium, pancuronium and pipecuronium in coronary surgical patients at risk. Anasthesiol Intensivmed Notfallmed Schmerzther. 1998;33(6):362-366.

23. Rahimzadeh P, Safari S, Faiz SHR, Alavian SM. Anesthesia for patients with liver disease. Hepat Mon. 2014;14(7):1-7.

24. Haas RE, Masters JE. Comparative recovery from three nondepolarizing neuromuscular blockers in a patient before and after chronic anticonvulsant therapy: a case report. AANA Journal. 1997;65(5):475-478.

25. Cope TM, Hunter JM. Selecting neuromuscular-blocking drugs for elderly patients. Drugs Aging. 2003;20(2):125-140.

26. Craig RG, Hunter JM. Neuromuscular blocking drugs and their antagonists in patients with organ disease. Anaesthesia. 2009;64(suppl 1):55-65.

27. Sangala W, Dixon J. Pancuronium and renal failure. Anaesthesia. 1987;42(11):1236.

28. Oliveri L, Plourdes G. Prolonged (more than ten hours) neuromuscular blockade after cardiac surgery. Can J Anaesth. 2005;52(1):88-93.

29. Nagaraja AS, Nagesha KA. A clinical study of intraocular pressure changes with vecuronium bromide and pancuronium bromide. Journal of Evolution of Medical and Dental Sciences. 2014;3(15):3887-3894.

30. Cote C. Pediatric anesthesia. In: Miller RD (ed). Miller's Anesthesia. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015: 2757-2798.

31. Rupp SM, Castagnoli KP, Fisher DM, Miller RD. Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. Anesthesiology. 1987;67(1):45-49.

32. Barnett SR. Eldrely patients. In: Pardo M Jr, Miller RD (eds). Basics of Anesthesia. 7th ed. Philadelphia, PA: Elsevier Saunders; 2011: 568-579.

33. Ingrande J, Hendrikus JML. Anesthetic pharmacology and the morbidly obese patient. Curr Anesthesiol Rep. 2013;3,(1):10-17.

34. Casati A, Putzu M. Anesthesia in the obese patient: pharmacokinetic considerations. J Clin Anesth. 2005;17(2):134-145.

35. Wilcox SR, Bittner EA, Elmer J, et al. Neuromuscular blocking agent administration for emergent tracheal intubation is associated with decreased prevalence of procedure-related complications. Crit Care Med. 2012;40(6):1808-1813.

36. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg. 2007;104(3):575-581.

37. Naguib M, Lien C, Meistelman C. Pharmacology of neuromuscular blocking drugs. In: Miller RD (ed). Miller's Anesthesia. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015: 958-994.

38. El-Baradie S. Neuromuscular efficacy and histamine-release hemodynamic changes produced by rocuronium versus atracurium: a comparitive study. J Egypt Natl Canc Inst. 2004;16(2):1007-1013.

39. Amin AM, Mohammad MY, Ibrahim MF. Comparative study of neuromuscular blocking and hemodynamic effects of rocuronium and cisatracurium under sevoflurane or total intravenous anesthesia. Middle East J Anesthesiol. 2009;20(1):39-51.

40. Rothenberg DM, O'Connor CJ, Tuman KJ. Anesthesia and the hepatobiliary system. In: Miller RD (ed). Miller's Anesthesia. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015: 2244-2261.

41. Servin FS, Lavaut E, Kleef U, Desmonts JM. Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane: a clinical and pharmacokinetic study. Anesthesiology. 1996;84(5):1092-1100.

42. van Miert MM, Eastwood NB, Boyd AH, Parker CJ, Hunter JM. The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. Br J Clin Pharmacol. 1997;44(2):139-144.

43. Robertson EN, DriessenJJ, Booij LH. Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure. Eur J Anaesthesiol. 2005;22(1):4-10.

44. Bock M, Haselmann L, Böettiger BW, Motsch J. Priming with rocuronium accelerates neuromuscular block in children: a prospective randomized study. Can J Anesth. 2007;54(7):538-543.

45. Meakin GH. Role of muscle relaxants in pediatric anesthesia. Cur Opin Anaesthesiol. 2007;20(3):227-231.

46. Woloszczuk-Gebicka B, Wyska E, Grabowski T. Sevoflurane increases fade of neuromuscular response to TOF stimulation following rocuronium administration in children: a PK/PD analysis. Paediatr Anesth. 2007;17(7):637-646.

47. Baykara N, Solak M, Toker K. Predicting recovery from deep neuromuscular block by rocuronium in the elderly. J Clin Anesth. 2003;15(5):328-333.

48. Sieber F, Pauldine R. Geriatric anesthesia. In: Miller RD (ed). Miller's Anesthesia. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015: 2407-2422.

49. Ingrande J, Lemmons HJ. Dose adjustments of anaesthetics in the morbidly obese. Br J Anaesth. 2010;105(Suppl 1):i16-i23.

50. Eckmann D. Anesthesia for bariatric surgery. In: Miller RD (ed). Miller's Anesthesia. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015: 2200-2216.

51. Pellis T, Leykin Y, Albano G, et al. Perioperative management and monitoring of a super-obese patient. Obes Surg. 2004;14(10):1423-1428.

52. Sherren PB, Tricklebank S, Glover G. Development of a standard operating procedure and checklist for rapid sequence induction in the critically ill. Scand J Trauma, Resusc Emerg Med. 2014;14(21):1-10.

53. Keles GT, Yentür, Cavuş Z, Zakarya M. Assessment of neuromuscular and haemodynamic effects of cisatracurium and vecuronium under sevoflurane-remifentanil anaesthesia in elderly patients. Eur J Anaesthesiol. 2004;21(11):877-881.

54. Basu R, Sinha I. Comparison of intra operative muscle relaxation and neuromuscular recovery from continuous infusion of vecuronium and atracurium in ASA grade I & II patients undergoing midline and paramedian laparotomies. Al Ameen J Med Sci. 2015;8(1):55-63.

55. Shah H, Bhavsar M, Upadhyaya R, Rathod H. Rocuronium vs vecuronium: a comparison of intubating condition, hemodynamic parameters and post-operative outcome in patients of coronary artery bypass graft surgery. International Journal of Biomedical and Advance Research. 2013;04(12):857-864.

56. Aronson JK. Neuromuscular blocking drugs and relaxants. In: Aronson JK (ed). Meyler's Side Effects of Drugs Used in Anesthesia. Amsterdam: Elsevier; 2009: 179-264.

57. Della Rocca G, Pompei L, Coccia MG, et al. Atracurium, cisatracurium, vecuronium and rocuronium in patients with renal failure. Minerva Anesthesiol. 2003;69(7-8):605-615.

58. Kainuma M, Miyake T, Kanno T. Extremely prolonged vecuronium clearance in a brain death case. Anesthesiology. 2001;95(4):1023-1024.

59. Holt NF. Renal disease. In: Hines RL, Marschall KE (eds). Stoelting's Anesthesia and Co-Existing Disease. 7th ed. Philadelphia, PA: Elsevier; 2012: 334-356.

60. Playfor S, Jenkins I, Boyles C, et al. Consensus guidelines for sustained neuromuscular blockade in critically ill children. Pediatr Anesth. 2007;17(9):881-887.

61. Rivera R, Antognini JF. Perioperative drug therapy in elderly patients. Anesthesiology. 2009;110(5):1176-1181.

62. Takaya T, Takeyama K, Miura M, Takiguchi M. The influence of body fat on the onset of vecuronium induced neuromuscular blockade. Tokai J Exp Clin Med. 2001;26(3):107-111.

63. Birks J. Conducting a safe rapid sequence induction in pre-hospital care. Trauma. 2016;18(2):1-5.

64. Miller Rd, Rupp SM, Fisher DM, Cronnelly R, Fahey MR, Sonh YJ. Clinical pharmacology of vecuronium and atracurium. Anesthesiology. 1984;61(4):444-453.

65. Raghavendra T. Neuromuscular blocking drugs: discovery and development. J R Soc Med. 2002;95(7):363-367.

66. Karnalkar A. Neuromuscular blockade of injectable atracurium and injectable vecuronium. Journal of Evidence-Based Medical Care. 2015;2(59):8976-8980.

67. Naguib M, Samarkandi AH, Bakhamees HS, Magboul MA, el-Bakry AK. Histamine release hemodynamic changes produced by rocuronium, vecuronium, mivacurium, atracurium and tubocurarine. Br J Anesth. 1995;75(5):588-592.

68. Singh A, Rao WRP, Ramakanth P. Volume of distribution of atracurium in different cohorts: a comparative study. Journal of Evidence-Based Medicine and Health Care. 2015;2(38):6001-6009.

69. Kies SJ, Pabelick CM, Hurley HA, White RD, Ackerman MJ. Anesthesia for patients with congenital long QT syndrome. Anesthesiology. 2005;102(1):204-210.

70. Ward S, Neill EA. Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure). Br J Anaesth. 1983;55(12):1169-1172.

71. Gyasi HK, Naguib M. Atracurium and severe hepatic disease: a case report. Can Anaesth Soc J. 1985;32(2):161-164.

72. Philip S, George S, Sunil G. Acute fatty liver of pregnancy complicating a twin pregnancy. Indian J Anaesth. 2014;58(1):73-75.

73. Bajwa SJS, Bajwa SK, Ghuman G. Pregnancy with co-morbidities: anesthetic aspects during operative intervention. Anesth Essays Res. 2013;7(3):294-301.

74. Warr J, Thiboutot Z, Rose L, Mehta S, Burry LD. Current therapeutic uses, pharmacology, and clinical considerations of neuromuscular blocking agents for critically ill adults. Ann Pharmacother. 2011;45(9):1116-1126.

75. SarinKapoor H, Kaur R, Kaur H. Anaesthesia for renal transplant surgery. Acta Anesthesiol Scand. 2007;51(10):1354-1367.

76. van Kralingen S, van de Garde EM, Knibbe C, et al. Comparative evaluation of atracurium dosed on ideal body weight vs. total body weight in morbidly obese patients. Br J Clin Pharmacol. 2011;71(1):34-40.

77. Konstadt SN, Reich DL, Stanley DE, et al. A two-center comparison of the cardiovascular effects of cisatracurium (Nimbex) and vecuronium in patients with coronary artery disease. Anesth Analg. 1995;81(5):1010-1014.

78. Searle NR, Thomson I, DuPont C, et al. A two-center study evaluating the hemodynamic and pharmacodynamic effects of cisatracurium and vecuronium in patients undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 1999;13(1):20-25.

79. Doenicke AW, Czeslick E, Moss J, Hoernecke R. Onset time, endotracheal intubating conditions, and plasma histamine after cisatracurium and vecuronium administration. Anesth Analg. 1998;87(2):434-438.

80. Amin AM, Mohammad MY, Ibriham MF. Comparative study of neuromuscular blocking and hemodynamic effects of rocuronium and cisatracurium under sevoflurane of total intravenous anesthesia. Middle East J Anesthesiol. 2009;20(1):39-51.

81. Lagneau F, D'honneur G, Plaud B, et al. A comparison of two depths of prolonged neuromuscular blockade induced by cisatracurium in mechanically ventilated critically ill patients. Intensive Care Med. 2002;28(12):1735-1741.

82. Eagar MA. The patient with cirrhosis who presents for non-hepatic surgery. Southern African Journal of Anaesthesia and Analgesia. 2011;17(1):120-123.

83. Ali MA, Ebied RS, Atallah MA, et al. Cisatracurium dose-response relationship in patients with chronic liver disease. Egyptian Journal of Anesthesia. 2014;30(2):197-202.

84. Lentschener C, Ozier Y. Anaesthesia for elective liver resection. Eur J Anesthesiol. 2002;19(11):780-788.

85. Fisher DM. Neuromuscular blocking agents in pediatric anaesthesia. Br J Anesth. 1999;83(1):58-64.

86. ShangGuan W, Lian Q, Li J, Gao F. Clinical pharmacology of cisatracurium during nitrous oxide-propofol anesthesia in children.J Clin Anesth. 2008;20(6):411-414.

87. Meakin GH, Meretoja OA, Perkins RJ, et al. Tracheal intubating conditions and pharmacodynamics following cisatracurium in infants and children undergoing halothane and thiopental-fentanyl anesthesia. Pediatr Anesth. 2007;17(2):113-120.

88. Leykin Y, Pellis T, Lucca M, Lomangina G, Marzano B, Gullo A. The effects of cisatracurium on morbidly obese women. Anesth Analg. 2004;99(4):1090-1094.

89. Gaszyński T, Gaszyński W, Strzelcyk J. General anaesthesia with remifentanil and cisatracurium for a superobese patient. Eur J Anesthesiol. 2003;20(1):77-78.

90. Claudius C, Garvey LH, Viby-Morgenson J. The undesirable effects of neuromuscular blocking drugs. Anaesthesia. 2009;64(Suppl 1):10-21.

91. Keegan MT. Prolongation of succinylcholine effect. In: Murray MJ, Rose SH, Wedel DJ, et al. (eds). Faust's Anesthesiology Review. 4th ed. Philadelphia, PA: Elsevier Saunders; 2015: 180-182.

92. Wong SF, Chung F. Succinylcholine associated postoperative myalgias. Anaesthesia. 2000;55(2):144-152.

93. Melnick B, Chalasani J, Uy NT, Phitayakorn P, Mallett SV, Rudy TE. Decreasing post-succinylcholine myalgias in outpatients.Can J Anaesth. 1987;34(3Pt1):238-241.

94. Blanié, Ract C, LeBlanc PE, et al. The limits of succinylcholine for critically ill patients. Anesth Analg. 2012;115(4):873-879.

95. Piotrowski AJ, Fendler WM. Hyperkalemia and cardiac arrest following succinycholine administration in a 16-year-old boy with acute nonlymphoblastic leukemia and sepsis. Pediatr Crit Care Med. 2007;8(2):183-185.

96. Roman CS, Rosin A. Succinylcholine-induced masseter muscle rigidity associated with rapid sequence intubation. Am J Emerg Med. 2007;25(1):102-104.

97. Bauer SJ, Orio K, Adams BD. Succinylcholine induced masseter spasm during rapid sequence intubation may require a surgical airway: a case report. Emerg Med J. 2005;22(6):456-458.

98. Martyn JJA. Succinylcholine hyperkalemia after burns. Anesthesiology. 1999;91:321-322.

99. Hunter JM. Muscle function and neuromuscular blockade. In: Aitkenhead AR, Moppett IK, Thompson JP (eds). Smith and Aitkenhead'sTextbook of Anaesthesia. 6th ed. London: Churchill Livingstone Elsevier; 2013: 87-104.

100. Hall JE. Renal regulation of potassium, calcium, phosphate, and magnesium; integration of renal mechanisms for control of blood volume and extracellular fluid volume. In: Hall JE, Guyton AC (eds). Guyton and Hall Textbook of Medical Physiology. 13th ed. Philadelphia, PA: Elsevier; 2016: 389-407.

101. Thapa S, Brull SJ. Succinylcholine-induced hyperkalemia in patients with renal failure: an old question revisited. Anesth Analg. 2000;91(1):237-241.

102. Stolworthy C, Haas RE. Malignant hyperthermia: a potentially fatal complication of anesthesia. Semin Perioper Nurs. 1998;7(1):58-66.

103. Visiou M, Young MC, Wieland K, Brandom BW. Anesthetic drugs and onset of malignant hyperthermia. Anesth Analg. 2014;118(2):388-396.

104. Hayes J, Veyckemans F, Bissonette B. Duchenne muscular dystrophy: an old anesthesia problem revisited. Pediatr Anesth. 2008;18(2):100-106.

105. U.S. Food and Drug Administration. Succinylcholine Package Insert. Lake Forest, IL: Hospira; 2010.

106. Brownstein D, Shugerman R, Cummings P, Rivera F, Copass M. Prehospital endotracheal intubation of children by paramedics. Ann Emerg Med. 1996;28(1):34-39.

107. Rose JB, Theroux MC, Katz MS. The potency of succinylcholine in obese adolescents. Anesth Analg. 2000;90(3):576-578.

108. Mayglothling J, Duane TM, Gibbs M, et al. Emergency tracheal intubation immediately following traumatic injury: an Eastern Association for the Surgery of Trauma practice management guideline. J Trauma Acute Care Surg. 2012;73(5 Suppl 4):S333-S340.

109. Sherren PB, Tricklebank S, Glover G. Development of a standard operating procedure and checklist for rapid sequence induction in the critically ill. Scand J Trauma Resusc Emerg Med. 2014;22:41.

110. Rodney G, Raju PK, Ball DR. Not just monitoring; a strategy for managing neuromuscular blockade. Anaesthesia. 2015;70(10):1105-1118.

111. Kervin MW. Residual neuromuscular blockade in the immediate postoperative period. J Perianesth Nurs. 2002;17(3):152-158.

112. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010;111(1):120-128.

113. Brull SJ, Murphy GS. Residual neuromuscular block: lessons unlearned. Part II: methods to reduce the risk of residual weakness. Anesth Analg. 2010;111(1):129-140.

114. Dabaene B, Beaussier M, Meistleman C, Donati F, Lienhart A. Monitoring the onset of neuromuscular block at the orbicularis oculi can predict good intubating conditions during atracurium-induced neuromuscular block. Anesth Analg. 1995;80(2):360-363.

115. McGrath CD, Hunter JM. Monitoring of neuromuscular block. BJA Educ. 2006;6(1):7-12.

116. Murphy GS, de Boer HD, Eriksson LI, Miller RD. Reversal (antagonism) of neuromuscular blockade. In: Miller RD, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Cohen NH, Young WL (eds). Miller's Anesthesia. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015: 995-1027.

117. Ghai B, Makkar JK, Wig J. Neuromuscular monitoring: a review. J Anaesth Clin Pharmacol. 2006;22(4):347-356.

118. Kopman AF, Zhaku B, Lai KS. The "intubating dose" of succinylcholine. Anesthesiology. 2003;99(5):1050-1054.

119. Srivastava A, Hunter JM. Reversal of neuromuscular block. Br J Anesth. 2009;103(1):115-129.

120. Farooq K, Hunter JM. Neuromuscular blocking agents and reversal agents. Anesth Intensive Care Med. 2011;12(6):266-270.

121. Nagelhout JJ. Reversal of neuromuscular blocking agents: current practice. AANA J. Suppl:8-11.

122. Kirkegaard-Nielsen H, Helbo-Hansen HS, Lindholm P, Severinsen IK, Pedersen HS, Jensen EW. Optimum time for neostigmine reversal of atracurium-induced neuromuscular blockade. Can J Anaesth. 1996;43(9):932-938.

123. Donati F, Lahoud J, McReady D, Bevan DR. Neostigmine, pyridostigmine, and edrophonium as antagonists of deep pancuronium blockade. Can J Anesth. 1987;34(6):589-593.

124. Kovac AL. Sugammadex: the first selective binding reversal agent for neuromuscular block. J Clin Anesth. 2009;21(6):444-453.

125. Nag K, Singh DR, Shetti AN, Kumar H, Sivashanmugam T, Parthasarathy S. Sugammadex: a revolutionary drug in neuromuscular pharmacology. Anesth Essays Res. 2013;7(3):302-306.

126. Lobaz S, Clymer M, Sammut M. Safety and efficacy of sugammadex for neuromuscular blockade reversal. Clin Med Insights Ther. 2014;6:1-14.

127. Vijayakumar E, Bosscher H, Renzi FP, Baker S, Heard SO. The use of neuromuscular blocking agents in the emergency department to facilitate tracheal intubation in the trauma patient: help or hindrance? J Crit Care. 1998;13(1):1-6.

128. Li J, Murphy-Lavoie H, Bugas C, Martinez J, Preston C. Complications of emergency intubation with and without paralysis. Am J Emerg Med. 1999;17(2):141-144.

129. Ma OJ, Atchley RB, Hatley T, Green M, Young J, Brady W. Intubation success rates improve for air medical program after implementing the use of neuromuscular blockers. Am J Emerg Med. 1998;16(2):125-127.

130. Brownstein D, Shugerman R, Cummings P, Rivera F, Copass M. Prehospital endotracheal intubation of children by paramedics. Ann Emerg Med. 1996;28(1):34-39.

131. Davis DP, Dunford JV, Poste JC, et al. The impact of hypoxia and hyperventilation on outcome after paramedic rapid sequence intubation of severely head-injured patients. J Trauma. 2004;57(1):1-8.

132. Bernard SA, Nguyen V, Cameron P, et al. Prehospital rapid sequence intubation improves functional outcome for patients with severe traumatic brain injury. Ann Surg. 2010;22(6):959-965.

133. Mallon WK, Keim SM, Shoenberger JM, Walls RM. Rocuronium vs. succinylcholine in the emergency department: a critical appraisal. J Emerg Med. 2009;37(2):183-188.

134. Perouansky M, Pearce RA, Hemmings HC Jr. Inhaled anesthetics. In: Miller RD, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Cohen NH, Young WL (eds). Miller's Anesthesia. 8th ed. Philadelphia, PA: Elsevier Saunders: 2015; 614-637.

135. Hall J. Regulation of respiration. In: Hall JE, Guyton AC (eds). Guyton and Hall's Textbook of Medical Physiology. 13th ed. Philadelphia, PA: Elsevier, Inc.; 2016; 539-549.

136. Yegneswaran B, Murugan R. Neuromuscular blockers and ARDS: thou shalt not breathe, move, or die! Crit Care. 2011;15(5):311.

137. Shehabi Y, Riker RR, Bokesch PM, et al. Delirium duration and mortality in lightly sedated, mechnically ventilated intensive care patients. Crit Care Med. 2010;38(12):2311-2318.

138. Pandit L, Agrawal A. Neuromuscular disorders in critical illness. Clin Neurol Neurosurg. 2006;108(7):621-627.

139. Schefold JC, Bierbrauer J, Weber-Carstens S. Intensive care unit-acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shock. J Cachexia Sarcopenia Muscle. 2010;1(2):147-157.

140. Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol. 2011;10(10):931-941.

141. Linos K, Foot C, Ziegenfuss M, Freeman WD, Tan KM. Critical illness weakness: common questions. Curr Anaesth Crit Care. 2007;18(5-6):252-260.

142. Kim TK, Obara S, Johnson KB. Basic principles of pharmacology. In: Miller RD (ed). Miller's Anesthesia. 8th ed. Philadelphia, PA: Elsevier/Saunders; 2015: 590-613.

143. Ortiz-Gómez JR, Carrascosa F, Pérez-Cajaraville JJ, Percaz-Baldos JA, Añez C. Comparative study of intubating conditions at the first minute with suxamethonium, rocuronium and different priming. Eur J Anesthesiol. 2005;22(4):263-268.

144. Ebert TJ. Autonomic nervous system pharmacology. In: Hemmings HC, Egan TD (eds). Pharmacology and Physiology for Anesthesia: Foundations and Clinical Application. Philadelphia, PA: Elsevier/Saunders; 2013: 282-299.

145. Roman J. FDA Panel Recommends Approval Of Merck Drug Sugammadex To Reverse Effect Of Muscle Relaxant. Available at https://www.techtimes.com/articles/104217/20151109/fda-panel-recommends-approval-of-merck-drug-sugammadex-to-reverse-effect-of-muscle-relaxant.htm. Last accessed March 19, 2020.

146. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg. 2007;104(3):575-581.

147. Dake. Neuromuscular Junction (Closer View). Available at https://commons.wikimedia.org/wiki/File:Synapse_diag4.png. Last accessed February 7, 2020.

148. Blaus B. Skeletal Muscle Fiber. Available at https://commons.wikimedia.org/wiki/File:Blausen_0801_SkeletalMuscle.png. Last accessed February 7, 2020.

149. Soto RG, Dunipace D. Mivacurium: return of a drug seeking an indication? ASA Monitor. 2017;81:30-31.

Evidence-Based Practice Recommendations Citations

1. Murray MJ, DeBlock H, Erstad B, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2016;44(11):2079-2103. Available at https://journals.lww.com/ccmjournal/Fulltext/2016/11000/Clinical_Practice_Guidelines_for_Sustained.16.aspx. Last accessed March 23, 2020.



Privacy Policy
Copyright © 2020 CE Resource, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.